Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Sungwoo | - |
dc.contributor.author | Jo, Jae-Cheol | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Yang, Deok-Hwan | - |
dc.contributor.author | Lim, Sung-Nam | - |
dc.contributor.author | Lee, Won-Sik | - |
dc.contributor.author | Kim, Won Seog | - |
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Hong, Dae-Sik | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.date.accessioned | 2021-08-11T10:23:39Z | - |
dc.date.available | 2021-08-11T10:23:39Z | - |
dc.date.issued | 2019-03 | - |
dc.identifier.issn | 2152-2669 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4711 | - |
dc.description.abstract | We assessed 53 patients aged >= 65 years in South Korea to evaluate the efficacy and toxicity of reduced-dose (RD) rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy for elderly patients with diffuse large B-cell lymphoma. RD-R-CHOP chemotherapy showed comparable survival benefits compared to those who received previous RD-R-CHOP-like chemotherapy. Introduction: Elderly patients are more prone to encounter some adverse factors when they receive chemotherapy compared to younger patients. Addition of rituximab to a reduced dose (RD) of cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy might improve patient outcomes with an improved toxicity profile when provided to elderly patients with diffuse large B-cell lymphoma. Patients and Methods: A total of 53 patients aged >= 65 years with diffuse large B-cell lymphoma diagnosed between August 2012 and December 2014 were enrolled onto this study. RD-R-CHOP regimen consisted of rituximab at 375 mg/m(2), cyclophosphamide at 600 mg/m(2), doxorubicin at 30 mg/m(2), and vincristine at 1 mg on day 1 of each cycle and 40 mg of prednisone on days 1 to 5. Patients received granulocyte colony-stimulating factor if they experienced grade 3/4 neutropenia or febrile neutropenia during any cycle. Results: The median follow-up duration was 18 months (range, 1-44 months). Complete response and overall response rates were 64.1% and 81.1%, respectively. Three-year event-free and overall survival rates were 45.7% +/- 8.4% and 62.7% +/- 8.1%, respectively. Grade 3/4 neutropenia occurred in 20 patients (37.7%), while febrile neutropenia occurred in 7 patients (20.7%). Conclusion: Outcomes of RD-R-CHOP chemotherapy were comparable to those of standard-dose R-CHOP or previous dose-adjusted R-CHOP chemotherapy. In the future, strategies such as tailored therapy based on geriatric assessment results are needed to determine the chemotherapeutic dosage. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Cancer Media Group | - |
dc.title | Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.clml.2018.11.003 | - |
dc.identifier.scopusid | 2-s2.0-85058694440 | - |
dc.identifier.wosid | 000459339200009 | - |
dc.identifier.bibliographicCitation | Clinical Lymphoma, Myeloma and Leukemia, v.19, no.3, pp 149 - 156 | - |
dc.citation.title | Clinical Lymphoma, Myeloma and Leukemia | - |
dc.citation.volume | 19 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 149 | - |
dc.citation.endPage | 156 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | NON-HODGKINS-LYMPHOMA | - |
dc.subject.keywordPlus | COLONY-STIMULATING FACTOR | - |
dc.subject.keywordPlus | FEBRILE NEUTROPENIA | - |
dc.subject.keywordPlus | PLUS RITUXIMAB | - |
dc.subject.keywordPlus | RESPONSE CRITERIA | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | CYCLOPHOSPHAMIDE | - |
dc.subject.keywordPlus | VINCRISTINE | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordAuthor | Chemotherapeutic dosage | - |
dc.subject.keywordAuthor | Lymphoproliferative disorders | - |
dc.subject.keywordAuthor | Older patients | - |
dc.subject.keywordAuthor | Prognostic factors | - |
dc.subject.keywordAuthor | Toxicity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.